Frontiers in Pharmacology (May 2024)

Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy

  • Liyan Sun,
  • Zhe Li,
  • Zhe Li,
  • Zhe Li,
  • Jinshuai Lan,
  • Jinshuai Lan,
  • Jinshuai Lan,
  • Ya Wu,
  • Tong Zhang,
  • Tong Zhang,
  • Tong Zhang,
  • Yue Ding,
  • Yue Ding,
  • Yue Ding

DOI
https://doi.org/10.3389/fphar.2024.1389922
Journal volume & issue
Vol. 15

Abstract

Read online

Combination therapies can enhance the sensitivity of cancer to drugs, lower drug doses, and reduce side effects in cancer treatment. However, differences in the physicochemical properties and pharmacokinetics of different therapeutic agents limit their application. To avoid the above dilemma and achieve accurate control of the synergetic ratio, a nanoscale co-delivery system (NCDS) has emerged as a prospective tool for combined therapy in cancer treatment, which is increasingly being used to co-load different therapeutic agents. In this study, we have summarized the mechanisms of therapeutic agents in combination for cancer therapy, nanoscale carriers for co-delivery, drug-loading strategies, and controlled/targeted co-delivery systems, aiming to give a general picture of these powerful approaches for future NCDS research studies.

Keywords